Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis

Cancer

Volumn 119, Issue 17, 2013, Pages 3234-3241

  Clevenger, Lauren ^a   Schrepf, Andrew ^a   Degeest, Koenraad ^b   Bender, David ^b   Goodheart, Michael ^b,c   Ahmed, Amina ^b   Dahmoush, Laila ^b   Penedo, Frank ^d   Lucci III, Joseph ^e   Thaker, Premal H ^f   Mendez, Luis ^g   Sood, Anil K ^h   Slavich, George M ⁱ   Lutgendorf, Susan K ^a,b,c  

^a University of Iowa   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MIAMI   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anxiety; depression; insomnia; ovarian cancer; quality of life

Indexed keywords

ADULT; ANXIETY; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; COMORBIDITY; DEPRESSION; DISTRESS SYNDROME; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RACE DIFFERENCE; SELF REPORT; SLEEP DISORDER; SLEEP PATTERN; SLEEP QUALITY; SURVIVAL TIME;

ANXIETY; DEPRESSION; INSOMNIA; OVARIAN CANCER; QUALITY OF LIFE;

ADULT; AGED; ANALGESICS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; DEPRESSION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SLEEP DISORDERS; STRESS, PSYCHOLOGICAL; UNITED STATES;

EID: 84882698171     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28188     Document Type: Article

References (49)

1. Anderson KO, Getto CJ, Mendoza TR, et al. Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. J Pain Symptom Manage. 2003; 25: 307-318.
2. Parker KP, Bliwise DL, Ribeiro M, et al. Sleep/wake patterns of individuals with advanced cancer measured by ambulatory polysomnography. J Clin Oncol. 2008; 26: 2464-2472.
3. Sela RA, Watanabe S, Nekolaichuk CL,. Sleep disturbances in palliative cancer patients attending a pain and symptom control clinic. Palliat Support Care. 2005; 3: 23-31.
4. Owen DC, Parker KP, McGuire DB,. Comparison of subjective sleep quality in patients with cancer and healthy subjects. Oncol Nurs Forum. 1999; 26: 1649-1651.
5. Kuo H, Chiu M, Liao W, Hwang SL,. Quality of sleep and related factors during chemotherapy in patients with stage I/II breast cancer. J Formos Med Assoc. 2009; 105: 64-69.
6. Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH,. Sleep and quality of life in breast cancer patients. J Pain Symptom Manage. 2002; 24: 471-480.
7. Redeker NS, Lev EL, Ruggiero J,. Insomnia, fatigue, anxiety, depression and quality of life of cancer patients undergoing chemotherapy. Sch Inq Nurs Pract. 2000; 14: 275-290.
8. Sandadi S, Frasure H, Broderick MJ, Waggoner SE, Miller JA, von Gruenigen VE,. The effect of sleep disturbance on quality of life in women with ovarian cancer. Gynecol Oncol. 2011; 123: 351-355.
9. Ancoli-Israel S, Liu L, Marler MR, et al. Fatigue, sleep and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer. 2006; 14: 201-209.
10. Thomas K, Bower J, Hoyt MA, Sepah S,. Disrupted sleep in breast and prostate cancer patients undergoing radiation therapy: the role of coping processes. Psychooncology. 2010; 19: 767-776.
11. Lindley C, Vasa S, Sawyer WT, Winer EP,. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer. J Clin Oncol. 1998; 16: 1380-1387.
12. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
13. Costanzo ES, Lutgendorf SK, Rothrock NE, Anderson B,. Coping and quality of life among women extensively treated for gynecologic cancer. Psychooncology. 2006; 15: 132-142.
14. Lin EM, Aikin JL, Good BC,. Premature menopause after cancer treatment. Cancer Pract. 1999; 7: 114-121.
15. Spiegel D,. Cancer and depression. Br J Psychiatry Suppl. 1996; 168: 109-116.
16. Palesh OG, Collie K, Batichok D, et al. A longitudinal study of depression, pain, and stress as predictors of sleep disturbance among women with metastatic breast cancer. Biol Psychol. 2007; 75: 37-44.
17. Bodourka-Bevers D, Basen-Engquist K, Carmack CL, et al. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol. 2000; 78: 302-308.
18. Hipkins J, Whitworth M, Tarrier N, Jayson G,. Social support, anxiety, and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol. 2004; 9: 569-581.
19. Price MA, Zachariae R, Butow PN, et al. Prevalence and predictors of insomnia in women with invasive ovarian cancer: anxiety a major factor. Eur J Cancer. 2009; 45: 3262-3270.
20. Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ,. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989; 28: 193-213.
21. Carpenter JS, Andrykowski MA,. Psychometric evaluation of the Pittsburgh Sleep Quality Index. J Psychosom Res. 1998; 45: 5-13.
22. Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A,. Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage. 2004; 27: 140-148.
23. Backhaus J, Junghanns K, Broocks A, Riemann D, Hohagen F,. Test-retest reliability and validity of the Pittsburgh Sleep Quality Index in primary insomnia. J Psychosom Res. 2002; 53: 737-740.
24. Radloff LS,. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977; 1: 385-401.
25. Hann D, Winter K, Jacobsen P,. Measurement of depressive symptoms in cancer patients: evaluation of the center for epidemiological studies depression scale (CES-D). J Psychosom Res. 1999; 46: 437-443.
26. Schroevers MJ, Sanderman R, van Sonderen E, Ronchor AV,. The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depress and positive affect in cancer patients and healthy reference subjects. Qual Life Res. 2000; 9: 1015-1029.
27. Shacham S,. A shortened version of the Profile of Mood States. J Pers Assess. 1983; 47: 305-306.
28. Lutgendorf SK, Mullen-Houser E, Russell D, et al. Preservation of immune function in cervical cancer patients during chemotherapy using a novel integrative approach. Brain Behav Immun. 2010; 24: 1231-1240.
29. Bradley S, Rose S, Lutgendorf S,. Quality of Life and mental health in cervical and endometrial cancer survivors. Gynecol Oncol. 2006; 100: 479-486.
30. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
31. Rubin S, ed. Society of Gynecologic Oncologists: Chemotherapy of Gynecologic Cancers. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.
32. Chou C, Bentler PM,. Model modification in covariance structure modeling: a comparison among likelihood ratio, lagrange multiplier, and wald tests. Multivariate Behav Res. 1990; 25: 115-136.
33. Littell RC, Pendergast J, Natarajan R,. Modelling covariance structure in the analysis of repeated measures data. Stat Med. 2000; 19: 1793-1819.
34. Kalueff AV, Nutt DJ,. Role of GABA in anxiety and depression. Depress Anxiety. 2007; 24: 495-517.
35. Barnes NM, Sharp T,. A review of central 5-HT receptors and their function. Neuropharmacology. 1999; 38: 1083-1152.
36. Berk M,. Sleep and depression: theory and practice. Aust Fam Physician. 2009; 38: 302-304.
37. Goff BA, Mandel LS, Melacon CH, Muntz HG,. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004; 291: 2705-2712.
38. Lutgendorf SK, Weinrib AZ, Penedo F, et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008; 26: 4820-4827.
39. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C,. Serum evaluation of interleukin 6 in ovarian cancer patients. Gyncol Oncol. 1997; 66: 27-30.
40. Clevenger L, Schrepf A, Christensen D, et al. Sleep disturbance, cytokines, and fatigue in women with ovarian cancer. Brain Behav Immun. 2012; 26: 1037-1044.
41. Maier SF, Watkins LR,. Cytokines for psychologists: implications of bidirectional immune-to-brain communications for understanding behavior, mood, and cognition. Psychol Rev. 1998; 105: 83-107.
42. Irwin M,. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun. 2002; 16: 503-512.
43. Smith MT, Haythornthwaite JA,. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004; 8: 119-132.
44. Theobald DE,. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone. 2004; 6 (suppl 1D): S15-S21.
45. Cho HJ, Lavretsky H, Olmstead R, Levin MJ, Oxman MN, Irwin MR,. Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study. Am J Psychiatry. 2008; 165: 1543-1550.
46. Irwin MR, Cole JC, Nicassio PM,. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychol. 2006; 25: 3-14.
47. Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T,. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008; 31: 489-495.
48. Carlson LE, Garland SN,. Impact of mindfulness-based stress reduction (MBSR) on sleep, mood, stress, and fatigue symptoms in cancer outpatients. Int J Behav Med. 2005; 12: 278-285.
49. Savard J, Simard S, Ivers H, Morin CM,. Randomized study on the efficacy of cognitive behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol. 2005; 23: 6083-9096.